In a business update, Pieris Pharmaceuticals warned that an ongoing clinical trial of its dry powder PRS-060/AZD1402 IL-4 receptor alpha inhibitor may take longer than expected, saying “Given the geopolitical situation, along with broader challenges amidst an ongoing pandemic, there is a heightened risk that more time will be required to deliver the topline study results by the end of the year as planned.” The company is partnered with AstraZeneca on development of the DPI for the treatment of moderate to severe asthma.
In January 2022, Pieris announced completion of part 1a of a Phase 2 study and said that it expected AstraZeneca to begin enrollment in part 2a of the study, with enrollment also continuing in part 1b. The company now says that “AstraZeneca is currently in the process of conducting a thorough timeline reforecast and working on strategies to mitigate any potential delays.”
Pieris may choose to exercise a co-development option following the study and will have an option in the future to co-commercialize the DPI in the US. The company also said that it expects to begin a Phase 1 trial of another inhaled candidate, PRS-220, which it is developing for the treatment of IPF, by the end of the year.
Read the Pieris press release.
